Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 DaysPrimary· assessed per 28 days during 12 week period; change from baseline and 12 weeks reported
Percent change in 28-day frequency of simple partial motor, and/or complex partial, and/or secondarily generalized tonic-clonic seizures during the 12 week treatment period relative to baseline
Group
Value
95% CI
YKP3089
55.6
-417.3 – 100.0
Placebo
21.5
-588.0 – 100.0
50% Responder RateSecondary· 12 weeks
Greater than or equal to 50% reduction in 28-day frequency of simple partial motor, and/or complex partial, and/or secondarily generalized tonic-clonic seizures during the 12 week treatment period relative to baseline.
Group
Value
95% CI
YKP3089
57
Placebo
24
Adverse events — posted to ClinicalTrials.gov
Time frame: 12 week double-blind treatment period plus taper period (2-3 weeks).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT02535091 — Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
· Phase 3
· completed
NCT01866111 — A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial
· Phase 2
· completed
NCT04513860 — Cenobamate Expanded Access Program (EAP)
· approved for marketing
Other recruiting trials for Partial Epilepsy
Currently open trials in the same condition.
NCT03478852 — Investigating Epilepsy: Screening and Evaluation
· recruiting
NCT01273129 — Surgery as a Treatment for Medically Intractable Epilepsy
· recruiting
Other SK Life Science, Inc. trials
Trials by the same sponsor.
NCT06453213 — Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
· Phase 4
· active not recruiting
NCT05572255 — A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Admini
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SK Life Science, Inc.
Last refreshed: recently
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01397968.